AstraZeneca results: Q1 2025
Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition
Revenue and EPS summary
| Q1 2025 | % Change | ||
| $m | Actual | CER1 | |
| -Product Sales | 12,875 | 6 | 9 |
| -Alliance Revenue | 639 | 40 | 42 |
| Product Revenue2 | 13,514 | 7 | 10 |
| Collaboration Revenue | 74 | 64 | 64 |
| Total Revenue | 13,588 | 7 | 10 |
| Reported EPS ($) | 1.88 | 34 | 32 |
| Core3 EPS ($) | 2.49 | 21 | 21 |
Key performance elements for Q1 2025
(Growth numbers at constant exchange rates)
* Total Revenue up 10% to $13,588m, driven by double-digit growth in Oncology and BioPharmaceuticals
* Growth in Total Revenue across all major geographic regions
* Core Operating profit increased 12%
* Core Tax rate of 16% in the quarter due to timing of settlements. Expectations for the full year Core tax rate are unchanged at 18-22%
* Core EPS increased 21% to $2.49
* Five positive Phase III readouts and 13 approvals in major regions since the prior results
Pascal Soriot, Chief Executive Officer, AstraZeneca, said:
“Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company.
Already this year we have announced five positive Phase III study readouts, including most recently the highly anticipated DESTINY-Breast09 for Enhertu, as well as SERENA-6 for camizestrant and MATTERHORN for Imfinzi; the latter two of these will feature in the ASCO 2025 plenary sessions, reflecting the significance of these data to the oncology community.
Our company is firmly committed to investing and growing in the US and we continue to benefit from our broad-based source of revenue and global manufacturing footprint, including eleven production sites in the US covering small molecules, biologics as well as cell therapy. Additionally, we have even greater US investment in manufacturing and R&D planned, leveraging our two large R&D sites in Gaithersburg MD and Cambridge MA.
Overall, we are making excellent progress toward our ambition of eighty billion dollars in Total Revenue by 2030.”
Guidance
AstraZeneca reiterates its Total Revenue and Core EPS guidance4 for FY 2025 at CER, based on the average foreign exchange rates through 2024.
Total Revenue is expected to increase by a high single-digit percentage
Core EPS is expected to increase by a low double-digit percentage
– The Core Tax rate is expected to be between 18-22%
– If foreign exchange rates for April 2025 to December 2025 were to remain at the average rates seen in March 2025, it is anticipated that compared to the performance at CER, FY 2025 Total Revenue would incur a low single-digit percentage adverse impact (unchanged from prior guidance), and Core EPS would incur a low single-digit percentage adverse impact (previously mid single-digit).
Notes
1. Constant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between periods in 2025 vs. 2024. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results.
2. Effective Jan 1 2025, the Group has updated its presentation of Total Revenue, adding a new subtotal of Product Revenue, the sum of Product Sales and Alliance revenue. For further details, see Note 1: ‘Basis of preparation and accounting policy’ in the Notes to the Interim Financial Statements.
3. Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Table 9 in the Financial Performance section of this document.
4. The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the cautionary statements section regarding forward-looking statements at the end of this announcement.